Shize Biotech completed a C/C+ round of financing worth 500 million yuan.

36Kr learned that Shize Biotech announced the successful completion of a RMB 500 million Series C/C+ market-based financing round, achieving market-based financing for six consecutive years. The round was co-led by China Guofeng Investment Fund and Jiangsu Industrial Investment and Social Security Fund. Yuyao Industrial Investment, BOC Capital, Shanghai Minhang Financial Investment, Shanghai Pudong Haitong Fund (Haitong Leading Area Mother Fund), Huajin Investment (under Zhuhai Science and Technology Industry Group), and Jiaxing Innote participated as follow-on investors. Existing shareholders such as Fengrui Capital, Suzhou Angel Mother Fund, Xinxi Capital, and Qisheng Capital continued to increase their investments. The funds from this financing will be used to further support the advancement of multiple "First-in-China" or "First-in-the-World" allogeneic universal iPSC-derived cell new drugs independently developed by Shize Biotech to the critical confirmatory clinical stage, enhance the company's large-scale and standardized production capacity of "off-the-shelf" neural cell new drugs and its quality management and control system, and ensure the accessibility of Shize Biotech's universal cell new drugs for commercial applications.